GLP-1 Medications Show Promise in Treating Addiction

A growing body of evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1s), initially developed for type 2 diabetes and weight loss, may similarly be effective in treating substance use disorders. Patients and clinicians are reporting reduced cravings for substances like alcohol, nicotine, and opioids in individuals taking these medications, prompting researchers to investigate a potential common biological pathway underlying addiction.

The Unexpected Benefit: Reduced Cravings

Reports of decreased cravings emerged anecdotally from patients taking GLP-1s for other conditions. A veteran with a decades-long smoking history found his interest in cigarettes vanished after starting a GLP-1 drug for diabetes, without actively trying to quit. Similarly, individuals struggling with alcohol dependence reported a diminished desire to drink . This pattern of reduced cravings across various addictive substances is unprecedented in addiction medicine.

How GLP-1s May Work

GLP-1 medications mimic the effects of the naturally occurring hormone GLP-1, which is produced in the gut and also active in the brain. In the brain, GLP-1 receptors are concentrated in regions controlling reward, motivation, and stress – areas heavily implicated in addiction . At therapeutic doses, GLP-1 drugs appear to dampen dopamine signaling in the brain’s reward center, potentially reducing the rewarding effects of addictive substances.

Animal studies support this theory. Rodents given GLP-1 drugs exhibited reduced alcohol consumption, cocaine self-administration, and decreased interest in nicotine. Research with green vervet monkeys, which voluntarily consume alcohol like humans, showed reduced alcohol intake without signs of discomfort, suggesting the drug lessened the reward value of alcohol rather than causing aversion .

Real-World Evidence from Veterans Affairs Data

Researchers analyzed data from over 600,000 U.S. Veterans with type 2 diabetes, comparing those who started GLP-1 medications to those who did not . The study, designed to mimic the rigor of randomized controlled trials, followed both groups for three years. The findings were striking:

• Reduced Mortality: A 50% reduction in deaths due to substance use among those taking GLP-1s.
• Fewer Overdoses: A 39% decrease in overdoses.
• Decreased Hospitalizations: A 26% reduction in drug-related hospitalizations.
• Lower Suicide Attempts: A 25% decrease in suicide attempts.
• Prevention of Modern Addictions: An 18% lower risk of developing alcohol use disorder, a 25% lower risk of opioid use disorder, and approximately a 20% lower risk of cocaine and nicotine dependence among those without prior substance use disorders.

Supporting Studies and Ongoing Research

A Swedish study of over 227,000 individuals with alcohol use disorder found a 36% lower risk of alcohol-related hospitalizations among those taking GLP-1 drugs, exceeding the reduction seen with naltrexone, a medication specifically approved for alcohol use disorder . Additional observational studies have linked GLP-1s to lower rates of cannabis use disorder relapse and reduced healthcare visits for nicotine dependence.

Several randomized controlled trials are underway to directly assess the efficacy of GLP-1s in treating addiction. Early results from trials of semaglutide and dulaglutide have shown promise in reducing craving and consumption of alcohol .

The Future of Addiction Treatment

GLP-1 drugs represent a novel approach to addiction treatment, potentially addressing a shared vulnerability across multiple substances. Unlike existing medications that target specific substances, GLP-1s may curb craving itself. These drugs are already widely prescribed by primary care physicians, offering an existing infrastructure for reaching millions of patients.

While further research is needed to address questions about long-term effects and potential impacts on motivation, the initial findings suggest that GLP-1 drugs could significantly improve addiction treatment and prevention. For individuals already considering GLP-1s for diabetes or obesity, the potential benefits for substance use disorders provide an additional factor to discuss with their healthcare provider.